Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Gimeno Vázquez, Eva
• dc.contributor.author Subirana Cachinero, Isaac
• dc.contributor.author Gómez Pérez, Miguel Angel
• dc.contributor.author Díaz, Javier
• dc.contributor.author Sanchez Gonzalez, Blanca
• dc.contributor.author García-Pallarols, Francesc
• dc.contributor.author Martínez, Laia
• dc.contributor.author Ble, Mireia
• dc.contributor.author Molina Ferragut, Luis
• dc.contributor.author Belarte Tornero, Laia Carla
• dc.contributor.author Abella Monreal, Eugenia
• dc.contributor.author Elosua Llanos, Roberto
• dc.contributor.author Comín Colet, Josep
• dc.contributor.author Salar Silvestre, Antonio
• dc.date.accessioned 2020-01-09T07:31:37Z
• dc.date.issued 2019
• dc.description.abstract OBJECTIVE: To evaluate the role of N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and a cardiovascular (CV) risk score named FRESCO for predicting anthracycline-induced cardiotoxicity (AIC) in diffuse large B-cell lymphoma (DLBCL). METHODS: A total of 130 consecutive DLBCL patients treated in first-line with anthracycline-containing immunochemotherapy. Competitive risk between NT-proBNP, FRESCO, and time to AIC was considered. RESULTS: Cumulative incidence of AIC was 12.2% and 17.5% at 1 and 5 years, respectively. Median time to development cardiotoxicity was 6.4 months, with half of the cases showing heart failure and the other half silent AIC. Both NT-proBNP levels and FRESCO score were independently associated with higher risk of AIC (P = 0.001 and P = 0.03, respectively). Patients with NT-proBNP ≥600 pg/mL or those with FRESCO ≥4.5% had 3.97 or 2.54 times higher risk of AIC than those with lower values (P = 0.001 and P = 0.048, respectively). According to the previous cutoffs, three groups of patients with a significantly different risk of AIC could be identified (P < 0.0001). CONCLUSIONS: Doxorubicin-containing chemotherapy is associated with increased risk of silent and overt AIC. Baseline NT-proBNP levels and FRESCO CV risk score are accurate predictors of AIC and can identify groups of patients at different risk, in which personalized cardiologic evaluation should be offered.
• dc.format.mimetype application/pdf
• dc.identifier.citation Ferraro MP, Gimeno-Vazquez E, Subirana I, Gómez M, Díaz J, Sánchez-González B, García-Pallarols F, et al. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. Eur J Haematol. 2019 Jun;102(6):509-515. DOI 10.1111/ejh.13234
• dc.identifier.doi http://dx.doi.org/10.1111/ejh.13234
• dc.identifier.issn 0902-4441
• dc.identifier.uri http://hdl.handle.net/10230/43238
• dc.language.iso eng
• dc.publisher Wiley
• dc.rights This is the peer reviewed version of the following article: Ferraro MP, Gimeno-Vazquez E, Subirana I, Gómez M, Díaz J, Sánchez-González B, García-Pallarols F, et al. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. Eur J Haematol. 2019 Jun;102(6):509-515, which has been published in final form at http://dx.doi.org/10.1111/ejh.13234. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword N-terminal pro-brain-type natriuretic peptide
• dc.subject.keyword Anthracyclines
• dc.subject.keyword Cardiotoxicity
• dc.subject.keyword Heart failure
• dc.subject.keyword Lymphoma
• dc.title Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion